Akero Therapeutics Says Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints
Portfolio Pulse from Benzinga Newsdesk
Akero Therapeutics announced that its Phase 2b SYMMETRY Cohort D study met safety and tolerability endpoints. EFX was well tolerated with comparable results between EFX and placebo groups, and the tolerability profile was similar to previous BALANCED and HARMONY studies.
June 05, 2023 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akero Therapeutics' Phase 2b SYMMETRY Cohort D study met safety and tolerability endpoints, indicating positive results for EFX and potential future success.
The positive results from the Phase 2b SYMMETRY Cohort D study indicate that EFX is well tolerated and has a consistent safety profile. This is important for investors as it demonstrates the potential for future success and regulatory approval of the drug, which could lead to increased revenues and stock price appreciation for Akero Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100